Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) Cost of Revenue (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Cost of Revenue for 13 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 138.9% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.2 million, a 2.11% decrease, with the full-year FY2025 number at $7.2 million, down 2.11% from a year prior.
  • Cost of Revenue was $3.0 million for Q4 2025 at Ekso Bionics Holdings, up from $1.3 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $3.0 million in Q4 2025 to a low of -$768000.0 in Q4 2021.
  • A 5-year average of $1.7 million and a median of $1.8 million in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 330.99% in 2022, then crashed 51.36% in 2024.
  • Ekso Bionics Holdings' Cost of Revenue stood at -$768000.0 in 2021, then surged by 330.99% to $1.8 million in 2022, then surged by 47.18% to $2.6 million in 2023, then plummeted by 51.36% to $1.3 million in 2024, then surged by 138.9% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Cost of Revenue are $3.0 million (Q4 2025), $1.3 million (Q3 2025), and $1.1 million (Q2 2025).